Evotec SE

EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: werner.lanthaler@evotec.com

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,766

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,631.5042.700.50%
CAC 407,826.791.34-0.02%
DAX 4024,226.49198.840.83%
Dow JONES (US)42,337.24734.171.76%
FTSE 1008,778.0560.080.69%
HKSE23,381.9999.660.43%
NASDAQ19,185.17447.972.39%
Nikkei 22537,724.11192.580.51%
NZX 50 Index12,582.3335.110.28%
S&P 5005,919.85117.032.02%
S&P/ASX 2008,407.6046.600.56%
SSE Composite Index3,340.696.15-0.18%

Market Movers